Pitcairn CO Denali Therapeutics Inc. Transaction History

Pitcairn CO

$1.67 Billion
Q3 2024

A detailed history of Pitcairn CO transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Pitcairn CO holds 11,259 shares of DNLI stock, worth $272,242. This represents 0.02% of its overall portfolio holdings.

Number of Shares

11,259

Holding current value

$272,242

% of portfolio

0.02%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2024 Nov 12, 2024	BUY	$20.96 - $31.05 $235,988 - $349,591	11,259 New	11,259 $327,000
Q2 2023 Jul 09, 2024	BUY	$23.37 - $32.96 $164,781 - $232,400	7,051 New	7,051 $208 Million

Others Institutions Holding DNLI

# of Institutions

228

Shares Held

120M

Call Options Held

60.6K

Put Options Held

48.4K

Baillie Gifford & CO

13.3M
Shares

$323 Million
0.3% of portfolio
Black Rock Inc. New York, NY

13.2M
Shares

$319 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

11.2M
Shares

$270 Million
0.01% of portfolio
Wellington Management Group LLP Boston, MA

10.7M
Shares

$259 Million
0.06% of portfolio
Capital Research Global Investors Los Angeles, CA

7.91M
Shares

$191 Million
0.05% of portfolio

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.24B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pitcairn CO, based on Form 13F filings with the SEC.

News

Stay updated on Pitcairn CO with notifications on news.

Account